Clinical trials
Completed Phase 1 Insulin Resistance trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
118 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 8 |
| 2007 | 5 |
| 2008 | 7 |
| 2009 | 10 |
| 2010 | 6 |
| 2011 | 9 |
| 2012 | 6 |
| 2013 | 6 |
| 2014 | 7 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 118 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stanford University | 6 |
| Columbia University | 5 |
| Halozyme Therapeutics | 4 |
| Gan and Lee Pharmaceuticals, USA | 3 |
| Mayo Clinic | 3 |
| Pennington Biomedical Research Center | 3 |
| University of Copenhagen | 3 |
| Washington University School of Medicine | 3 |
| Albert Einstein College of Medicine | 2 |
| AstraZeneca | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Insulin Resistance | 118 |
| Diabetes Mellitus | 20 |
| Diabetes Mellitus, Type 2 | 20 |
| Obesity | 14 |
| Diabetes Mellitus, Type 1 | 11 |
| Inflammation | 6 |
| Glucose Intolerance | 5 |
| Hyperinsulinism | 5 |
| Prediabetic State | 5 |
| Cardiovascular Diseases | 4 |
Trials
Showing 1 to 25 of 118. Each trial links to its page on Pharma Observatory.
18 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.